Key result
High admission monocytes linked to ~32% higher odds of high thrombus burden during STEMI PPCI.
Why the study?
The study aimed to establish the frequency of high versus low thrombus burden in STEMI patients undergoing PPCI and compare mean monocyte counts between the groups.
Does admission monocyte count predict high thrombus burden in STEMI patients undergoing primary PCI?
Cross-Sectional (n=178)
No
Does admission monocyte count predict high thrombus burden in STEMI patients undergoing primary PCI?
Odds Ratio: 1.318 (95% CI 1.14–1.524)
p-value: p=0.00
Higher admission monocyte count is an independent predictor of high thrombus burden in patients with STEMI undergoing primary PCI.
Admission monocyte count may support early risk stratification in STEMI; leaves open prospective validation before guiding therapy.
Introduction Primary percutaneous coronary intervention (PPCI) in ST-elevation myocardial infarction (STEMI) patients can lead to poor outcomes. Intra-coronary thrombus development due to atherosclerotic plaque rupture and coronary blood flow blockage causes STEMI. Intracranial thrombosis in STEMI patients is fatal. It was our goal to establish how often patients with STEMI underwent PPCI with a high thrombus burden versus a low thrombus burden and to compare the mean monocyte count between the two groups. Material and methods This cross-sectional study was conducted at KRL Hospital Islamabad from October 2021 to March 2022. At a 95% level of confidence, a 5% margin of error, and keeping a population size of 330, a sample size of 178 was obtained using the Raosoft sample size calculator (Raosoft, Inc., Seattle, WA). The non-probability consecutive sampling method was used. All patients with STEMI undergoing PPCI, aged between 18 and 80 years, and presenting within 24 hours of symptoms were included in our study. Pre-PPCI pharmacological treatment given within three hours of the onset of a heart attack to stabilize patients with myocardial infarction included aspirin, clopidogrel, and an intravenous bolus of 70 U/kg of body weight of un-fractionated heparin. The collected data were analyzed using SPSS version 26.0 (IBM Corp., Armonk, NY). Fisher's exact test was employed, and a p-value of less than 0.05 was deemed statistically significant. The odds ratio and confidence interval were also calculated. Results A total of 178 participants were included in the research, out of which males were predominant with more than half of the study population. The mean age in patients having a low thrombus burden was 37.75 ± 6.39 years and that of patients with a high thrombus burden was mean 56.04 ± 7.98 years. In high thrombus burden patients, diabetes mellitus was found in 98.3%, hypertension in 120 patients (100%), obesity in (60%), and tobacco consumption in 120 patients (100%). The mean monocyte count in high burden patients was 70.27 ± 3.24, whereas it was 61.89 ± 5.71 in low burden patients. Only five patients had a Thrombolysis In Myocardial Infarction (TIMI) score of 5 while 34.8% of patients arrived in three to six hours and 12.9% arrived in less than three hours. Patients with a high monocyte count have 1.3 times more chances of developing the disease when the monocyte count was high (OR = 1.318, 95% CI = 1.140-1.524). Conclusion Patients with STEMI undergoing PPCI had a higher monocyte count upon admission, which was an independent clinical predictor of a high thrombus burden. Our findings suggest that admission monocyte count may be available for early risk stratification of high-thrombus burden in acute STEMI patients and might allow the optimization of anti-thrombotic therapy to improve the outcomes of PPCI.
No takes yet. Share an insight, caveat, or question.
Zeeshan et al. (2022) conducted a cross-sectional in ST-Segment Elevated Myocardial Infarction (STEMI) (n=178). High monocyte count vs. Low monocyte count was evaluated on High thrombus burden (OR 1.318, 95% CI 1.140-1.524, p=0.00). Patients with a high monocyte count on admission had 1.3 times higher odds of having a high thrombus burden during primary percutaneous coronary intervention for STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: